Keyword |
Occurrences |
Avg. pub. year |
Avg. citations |
covid-19 |
12 |
2021.1667 |
12.6667 |
biologic |
10 |
2021.1 |
12.6 |
benralizumab |
28 |
2020.8929 |
11.5357 |
dupilumab |
77 |
2020.8442 |
14.1039 |
reslizumab |
13 |
2020.6154 |
17.8462 |
biologics |
84 |
2020.6071 |
16.119 |
type-2 inflammation |
10 |
2020.6 |
13.4 |
type 2 inflammation |
69 |
2020.5652 |
24.4638 |
monoclonal antibody |
15 |
2020.2667 |
7.8667 |
patient-reported outcome measure |
10 |
2020 |
9.7 |
severe asthma |
31 |
2020 |
15.129 |
mepolizumab |
42 |
2019.9048 |
28.4286 |
crswnp |
82 |
2019.8902 |
11.7073 |
crssnp |
16 |
2019.875 |
18.9375 |
endotypes |
39 |
2019.8462 |
40.9487 |
chronic rhinosinusitis with nasal polyps (crswnp) |
19 |
2019.8421 |
13.7895 |
monoclonal antibodies |
22 |
2019.7727 |
12.5455 |
medical therapy of chronic rhinosinusitis |
11 |
2019.7273 |
11.8182 |
omalizumab |
55 |
2019.7273 |
18.5636 |
biologicals |
13 |
2019.6923 |
24.3846 |